Nanoentek America, Inc.

Nanoentek America, Inc., a Korea-based manufacturer of biotechnology research equipment and medical devices operating as a U.S. sales and distribution entity, supplies specialized diagnostic instruments, consumable reagent kits, and live-cell imaging systems to federal health agencies and military treatment facilities as a prime contractor (100% of recent awards) on full-and-open purchase orders with no set-aside designations. The company operates from Waltham, Massachusetts, and is foreign-owned; recent activity spans twenty-seven purchase orders totaling $1.5 million in combined potential value across seven distinct customer agencies over the past several years.

Nanoentek's federal footprint concentrates heavily on defense and veterans' healthcare customers. The Defense Health Agency dominates by both award count and dollars, accounting for eleven awards worth $928 thousand combined potential value — representing 62% of total potential value. The Department of the Navy Bureau of Medicine and Surgery (six awards, $286 thousand) and the Department of the Army Medical Command (six awards, $170 thousand) follow, with the Department of Veterans Affairs Veterans Health Administration Integrated Service Networks 12 and 7 filling out the active set. The top three customers account for 93% of recent awards and 97% of combined potential value.

Nanoentek's capability portfolio centers on residual white blood cell (rWBC) diagnostic equipment, consumable test kits, and real-time live-cell imaging systems. Representative named contracts include a $78,053 firm fixed-price order from the Defense Health Agency (awarded October 1, 2024) for ADAM Residual White Blood Cell kits and drop shipment services supporting Naval Hospital Okinawa through September 2029; a $159,066 order from DHA (January 14, 2025) for consumable kits for blood testing at Tripler Army Medical Center, Hawaii, running through September 2030; a $39,375 total small-business-set-aside order from the Department of Veterans Affairs Veterans Health Administration (July 1, 2025) for a JuLI Stage Live Cell Imaging System to support the Ralph H. Johnson VA Medical Center in Charleston, South Carolina; and a $24,600 purchase order from the National Institute of Neurological Disorders and Stroke (September 19, 2024) for a JuLiStage real-time live cell imaging system. NAICS categorization is split across Surgical and Medical Instrument Manufacturing (16 awards), In-Vitro Diagnostic Substance Manufacturing (5 awards), and Electromedical and Electrotherapeutic Apparatus Manufacturing (2 awards). PSC codes cluster in Medical and Surgical Instruments (12 awards), Drugs and Biologicals (5 awards), and In Vitro Diagnostic Substances (4 awards).

Activity has been sporadic — two to four awards per year from 2021 through 2024, with three awards in 2025. Combined dollars obligated stand at $1.1 million (72% of combined potential value), indicating performance momentum on recent orders. All recent work takes the form of firm fixed-price purchase orders with no parent vehicle or subcontracting footprint; the company operates as a direct prime supplier of branded medical equipment and consumables rather than through IDIQs, GWACs, or BPAs.